GO:0097070 ductus arteriosus closure: Postnatal Vascular Remodeling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097070 ductus arteriosus closure describes the morphogenesis process in which the ductus arteriosus, the fetal shunt between the aorta and pulmonary artery, changes to no longer permit blood flow after birth.
• Functional closure of the ductus arteriosus occurs within the first hours to days of life through smooth muscle constriction, while anatomic closure involves intimal cushion formation, endothelial remodeling and apoptosis.
• Oxygen tension, prostaglandin E2 withdrawal, and platelet-mediated thrombosis are central regulators of ductus arteriosus closure in term and preterm infants.
• Patent ductus arteriosus (PDA) is a common complication of prematurity, and persistent patency is associated with pulmonary overcirculation, systemic hypoperfusion and increased morbidity.
• Pharmacologic closure with cyclooxygenase inhibitors and transcatheter or surgical closure are established clinical interventions for PDA, though renal and other safety considerations remain under study.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models enable causal dissection of genes such as PTGS2, PTGER4, TGFB1 and NOTCH1 in ductus arteriosus closure biology.
Description
The ductus arteriosus is a fetal vascular shunt that connects the pulmonary artery to the descending aorta, allowing blood to bypass the non-aerated lungs during intrauterine life. After birth, this vessel must close promptly to establish the normal parallel circulation of the neonate, and the biological process governing this transition is annotated as GO:0097070 ductus arteriosus closure. Failure of this process results in patent ductus arteriosus (PDA), one of the most common congenital cardiovascular abnormalities, particularly in preterm infants. Understanding the molecular and mechanical factors that drive ductus arteriosus closure is therefore of direct clinical and research importance. GO:0097070 encompasses the morphogenetic changes by which the ductus arteriosus ceases to permit blood flow after birth. This process integrates oxygen sensing, prostaglandin metabolism, platelet activation, extracellular matrix remodeling and programmed cell death within the vessel wall. Research into this term spans developmental biology, neonatology, vascular biology and pharmacology, and it is increasingly studied using genetically engineered animal models and human cell systems. For researchers, GO:0097070 provides a structured framework for interrogating the genes and pathways that control postnatal vascular remodeling. Because the ductus arteriosus is a transient structure with a defined developmental window, it offers a tractable model for studying how environmental cues such as oxygen and circulating mediators are translated into durable anatomic changes. This article reviews the definition, mechanisms, key genes, disease links and experimental methods relevant to ductus arteriosus closure.
ductus arteriosus closure At A Glance
| GO ID | GO:0097070 |
|---|---|
| GO term | ductus arteriosus closure |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Postnatal morphogenesis of the ductus arteriosus to cease permitting blood flow |
| Anatomical context | Shunt between the aorta and pulmonary artery that bypasses the fetal lungs |
| Key triggers | Increased oxygen tension, withdrawal of prostaglandin E2, platelet activation |
| Clinical relevance | Failure results in patent ductus arteriosus, especially in preterm infants |
| Research models | Neonatal animal models, vascular smooth muscle cells, genetically engineered mice |
What Is GO:0097070?
GO:0097070 ductus arteriosus closure is defined as the morphogenesis process in which the ductus arteriosus changes to no longer permit blood flow after birth. The ductus arteriosus is the shunt between the aorta and the pulmonary artery that allows blood to bypass the fetus' lungs. This term therefore covers the structural and functional transformation of the vessel from a patent fetal shunt into a closed, ligamentous remnant.
Why Is ductus arteriosus closure Important in Cell Biology?
Ductus arteriosus closure is essential for the transition from fetal to neonatal circulation, and its failure is a leading cause of morbidity in preterm infants. Patent ductus arteriosus can lead to pulmonary overcirculation, systemic hypoperfusion, and increased risk of intraventricular hemorrhage and chronic lung disease. Understanding the molecular mechanisms of closure informs pharmacologic and interventional strategies, including cyclooxygenase inhibitors and transcatheter closure.
• Ductus arteriosus closure is required for normal postnatal circulatory adaptation.
• Patent ductus arteriosus is one of the most common congenital cardiovascular findings in preterm infants.
• Oxygen tension and prostaglandin E2 gradients are central physiologic regulators of closure.
• Platelet activation and thrombus formation contribute to functional closure of the ductus.
• Cyclooxygenase inhibitors are used pharmacologically to promote closure in neonates.
• Transcatheter closure is an established intervention for persistent PDA.
• Renal function and other safety outcomes after transcatheter closure are active areas of research.
• Genetic and molecular studies of closure inform developmental vascular biology.
• Animal models of ductus arteriosus closure provide insight into human neonatal disease.
• GO:0097070 supports systematic annotation of genes and pathways in postnatal vascular remodeling.
What Happens During ductus arteriosus closure?
Functional constriction of the ductus arteriosus
In simple terms: The ductus arteriosus first narrows by muscle contraction shortly after birth.
Functional closure of the ductus arteriosus begins within minutes to hours after birth and is driven primarily by increased oxygen tension and a decline in circulating prostaglandin E2. The muscular media of the ductus responds to oxygen by depolarizing smooth muscle cells and increasing intracellular calcium, leading to vasoconstriction. This initial constriction reduces blood flow through the shunt and is reversible under certain conditions, such as in preterm infants with immature oxygen sensing.
Prostaglandin withdrawal and oxygen sensing
In simple terms: Loss of prostaglandins and higher oxygen levels signal the vessel to stay closed.
Prostaglandin E2, produced largely by the placenta and ductus itself, maintains patency in utero by relaxing ductal smooth muscle. After birth, removal of the placenta and increased pulmonary prostaglandin clearance reduce PGE2 levels, while rising arterial oxygen tension promotes constriction. The interplay between oxygen-sensitive potassium channels, cytochrome P450-derived metabolites and prostaglandin receptors determines the tone of the ductus.
Platelet activation and thrombotic occlusion
In simple terms: Platelets help seal the narrowed ductus by forming a clot.
As the ductus constricts, platelet activation and aggregation contribute to functional closure by forming a thrombus within the lumen. Studies in neonates have linked platelet counts and function to the success of ductus arteriosus closure, although the relationship is complex and may be modified by other clinical factors. Platelet-mediated occlusion is considered an important component of the transition from a narrowed vessel to a non-perfused one.
Intimal cushion formation and anatomic remodeling
In simple terms: The inner wall of the ductus thickens and remodels to close it permanently.
Anatomic closure involves intimal cushion formation, in which smooth muscle cells and extracellular matrix components migrate and accumulate beneath the endothelium. This process is accompanied by endothelial cell apoptosis, elastic fiber degradation and deposition of collagen, leading to the formation of the ligamentum arteriosum. Growth factors such as TGFB1 and Notch signaling components regulate these remodeling events.
Apoptosis and vascular remodeling
In simple terms: Programmed cell death helps remove cells and reshape the closing vessel.
Apoptosis of smooth muscle cells and endothelial cells is a hallmark of the later stages of ductus arteriosus closure. Hypoxia-inducible factors, reactive oxygen species and mitochondrial pathways have been implicated in triggering programmed cell death within the ductal wall. This remodeling converts the muscular ductus into a fibrous remnant and ensures permanent closure.
Key Genes Involved in GO:0097070 ductus arteriosus closure
The following genes and proteins have been implicated in the regulation of ductus arteriosus closure based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTGS2 | Cyclooxygenase-2 mediated prostaglandin synthesis | Target of pharmacologic closure strategies |
| PTGS1 | Cyclooxygenase-1 mediated prostaglandin synthesis | Contributes to ductal prostaglandin tone |
| PTGER4 | Prostaglandin E2 receptor EP4 | Mediates PGE2-induced ductal relaxation |
| PTGER2 | Prostaglandin E2 receptor EP2 | Modulates ductal smooth muscle tone |
| TGFB1 | Transforming growth factor beta 1 | Regulates intimal cushion formation and remodeling |
| NOTCH1 | Notch signaling receptor | Controls vascular remodeling and cell fate in the ductus |
| NOTCH3 | Notch signaling receptor | Expressed in ductal smooth muscle; involved in maturation |
| HIF1A | Hypoxia-inducible factor 1 alpha | Oxygen sensing and transcriptional response in the ductus |
| EPAS1 | Endothelial PAS domain protein 1 (HIF2A) | Oxygen-sensitive regulation of ductal gene expression |
| KCNJ8 | Potassium inwardly rectifying channel subfamily J member 8 | Oxygen-sensitive potassium channel in ductal smooth muscle |
| ABCC9 | ATP binding cassette subfamily C member 9 | Forms SUR2B subunit of KATP channels in the ductus |
| CYP2C9 | Cytochrome P450 family 2 subfamily C member 9 | Generates vasoactive eicosanoids affecting ductal tone |
| CYP2C8 | Cytochrome P450 family 2 subfamily C member 8 | Contributes to epoxyeicosatrienoic acid production |
| EDN1 | Endothelin 1 | Vasoactive peptide influencing ductal constriction |
| NOS3 | Nitric oxide synthase 3 | Endothelial nitric oxide modulates ductal tone |
| VEGFA | Vascular endothelial growth factor A | Angiogenic remodeling of the ductus |
| ACTA2 | Actin alpha 2, smooth muscle | Contractile apparatus of ductal smooth muscle cells |
How Is ductus arteriosus closure Regulated?
Ductus arteriosus closure is regulated by a combination of oxygen tension, prostaglandin signaling, platelet function and developmental gene expression programs. Oxygen acts through potassium channels and calcium signaling to depolarize ductal smooth muscle, while prostaglandin E2 maintains patency through EP2 and EP4 receptors. Platelet activation and thrombus formation contribute to functional occlusion, and growth factor signaling pathways including TGFB1 and Notch coordinate anatomic remodeling. The process is also influenced by gestational age, with immature infants showing altered oxygen sensing and prostaglandin metabolism.
ductus arteriosus closure and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGS2 | Patent ductus arteriosus; prostaglandin synthesis | Knockout mouse; point mutation of catalytic residues |
| PTGER4 | Patent ductus arteriosus; PGE2 signaling | Knockout mouse; conditional knockout in smooth muscle |
| TGFB1 | Ductal remodeling; intimal cushion formation | Knock-in reporter; overexpression in vascular cells |
| NOTCH1 | Vascular remodeling; ductus closure | Knockout mouse; point mutation in ligand-binding domain |
| HIF1A | Oxygen sensing; ductal gene expression | Conditional knockout; hypoxia challenge models |
Patent ductus arteriosus in preterm infants
Failure of ductus arteriosus closure results in patent ductus arteriosus, a condition that is particularly common in preterm infants due to immature oxygen sensing and altered prostaglandin metabolism. Persistent patency leads to left-to-right shunting, pulmonary overcirculation and systemic hypoperfusion, which are associated with increased morbidity. Clinical management includes cyclooxygenase inhibitors, fluid restriction and, when necessary, transcatheter or surgical closure.
Pharmacologic and interventional closure
Cyclooxygenase inhibitors such as indomethacin and ibuprofen are used to promote ductus arteriosus closure by reducing prostaglandin synthesis. When pharmacologic therapy fails or is contraindicated, transcatheter closure is an established alternative, and outcomes including renal function have been studied in very preterm infants. The choice of strategy depends on gestational age, clinical stability and local expertise.
Genetic and developmental contributions
Genetic variation in prostaglandin pathway genes, oxygen-sensing pathways and vascular remodeling genes may influence the likelihood of ductus arteriosus closure. Animal models with targeted deletions of genes such as PTGS2, PTGER4 and TGFB1 have provided insight into the molecular requirements for closure. These findings support the use of genetically engineered models to dissect causal mechanisms.
From ductus arteriosus closure-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is PTGS2 required for ductus arteriosus closure? | PTGS2 knockout mouse |
| Does a point mutation in PTGER4 alter ductal tone? | PTGER4 point-mutation knock-in mouse |
| Can TGFB1 overexpression rescue closure defects? | TGFB1 overexpression transgenic mouse |
| Where is NOTCH1 expressed during closure? | NOTCH1-tagged knock-in reporter mouse |
| Does platelet depletion delay closure? | Platelet-depleted neonatal mouse model |
| Does oxygen tension regulate KCNJ8 expression? | KCNJ8 knockout and hypoxia exposure models |
How to Study the ductus arteriosus closure Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Histology and immunofluorescence | Tissue architecture and protein localization | Assessing intimal cushion formation |
| RNA sequencing | Transcriptome changes during closure | Identifying closure-associated genes |
| Single-cell RNA sequencing | Cell-type-specific expression programs | Resolving smooth muscle and endothelial contributions |
| Mass spectrometry | Prostaglandin and eicosanoid levels | Quantifying mediators of ductal tone |
| Echocardiography | Ductus arteriosus patency and flow | Monitoring closure in neonatal models |
| Platelet function assays | Platelet activation and aggregation | Linking platelets to functional closure |
| CRISPR gene editing | Causal gene function | Testing candidate genes in models |
Histology and immunofluorescence
Histological sectioning and immunofluorescence can visualize intimal cushion formation, smooth muscle organization and apoptosis within the ductus arteriosus during closure. Markers such as ACTA2, CD31 and cleaved caspase-3 help define cellular changes across developmental stages.
Transcriptomics and single-cell RNA sequencing
RNA sequencing of ductus arteriosus tissue at multiple postnatal time points can identify gene expression programs associated with functional and anatomic closure. Single-cell approaches can resolve contributions of smooth muscle, endothelial and immune cell populations.
Prostaglandin and eicosanoid profiling
Mass spectrometry-based profiling of prostaglandins and related eicosanoids quantifies the mediators that maintain patency or promote closure. Such measurements can be combined with genetic perturbations to link specific enzymes to ductal tone.
In vivo vascular physiology
Echocardiography and invasive pressure-flow measurements in neonatal animal models assess ductus arteriosus patency and closure dynamics. These methods are essential for validating molecular hypotheses in a physiological context.
How CRISPR Can Be Used to Study GO:0097070 ductus arteriosus closure
Knockout
CRISPR knockout of candidate genes such as PTGS2, PTGER4 or TGFB1 in mice or cell models can test whether they are required for ductus arteriosus closure. Knockout models allow assessment of functional closure, anatomic remodeling and gene expression changes.
Point Mutation
Point mutations can be introduced to dissect specific domains or catalytic residues, for example in prostaglandin receptors or oxygen-sensing channels. Such models help distinguish loss-of-function from dominant-negative or gain-of-function effects.
Knock-in
Knock-in of reporters or epitope tags enables visualization of gene expression and protein localization during closure. Tagged knock-in models are valuable for tracking cell lineages and protein interactions in the ductus arteriosus.
Overexpression
Overexpression of genes such as TGFB1 or VEGFA can test whether increased signaling is sufficient to alter closure dynamics. These models complement knockout studies by probing gain-of-function mechanisms.
How EDITGENE Supports ductus arteriosus closure Research
Researchers studying ductus arteriosus closure-related genes often need to determine whether a candidate gene is causally involved in functional or anatomic closure, and CRISPR-based models provide a rigorous way to test such hypotheses.
Contact EDITGENE today to design your custom CRISPR model for ductus arteriosus closure research.
Frequently Asked Questions About ductus arteriosus closure
What is GO:0097070 ductus arteriosus closure?
GO:0097070 is a Gene Ontology biological process term describing the morphogenesis process in which the ductus arteriosus changes to no longer permit blood flow after birth.
What is the ductus arteriosus?
The ductus arteriosus is a fetal blood vessel connecting the pulmonary artery to the aorta that allows blood to bypass the lungs before birth.
Why does the ductus arteriosus need to close after birth?
Closure is required to establish normal postnatal circulation and prevent left-to-right shunting that can cause pulmonary overcirculation and systemic hypoperfusion.
What genes are involved in ductus arteriosus closure?
Genes such as PTGS2, PTGER4, TGFB1, NOTCH1, HIF1A and KCNJ8 have been implicated in the regulation of ductus arteriosus closure.
What is patent ductus arteriosus?
Patent ductus arteriosus is the persistence of the fetal shunt after birth, most commonly seen in preterm infants, and is associated with increased morbidity.
How is patent ductus arteriosus treated?
Treatment options include cyclooxygenase inhibitors, fluid restriction, transcatheter closure and surgical ligation depending on clinical context.
What role do platelets play in ductus arteriosus closure?
Platelet activation and thrombus formation contribute to functional occlusion of the constricting ductus arteriosus.
What is the role of prostaglandins in ductus arteriosus closure?
Prostaglandin E2 maintains ductal patency in utero, and its withdrawal after birth promotes constriction and closure.
How do researchers study ductus arteriosus closure?
Researchers use animal models, histology, RNA sequencing, prostaglandin profiling, echocardiography and CRISPR gene editing to study closure mechanisms.
Can CRISPR be used to study ductus arteriosus closure genes?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models can test the causal role of candidate genes in ductus arteriosus closure.
Conclusion
GO:0097070 ductus arteriosus closure captures a critical postnatal vascular remodeling process that is essential for neonatal circulatory adaptation. Its failure leads to patent ductus arteriosus, a common and clinically significant condition, particularly in preterm infants. Molecular studies have identified key roles for oxygen sensing, prostaglandin signaling, platelet function and growth factor pathways in closure. Continued research using genetically engineered models and advanced profiling methods will further clarify the mechanisms and inform therapeutic strategies.
References
- 1. Hallman M et al.. 2021. Early closure mechanisms of the ductus arteriosus in immature infants.. Acta Paediatr 110(7):1995-2007 PMID: 33655615
- 2. Crockett SL et al.. 2019. Molecular and mechanical factors contributing to ductus arteriosus patency and closure.. Congenit Heart Dis 14(1):15-20 PMID: 30468303
- 3. Manica JLL et al.. 2022. Percutaneous Closure of Ductus Arteriosus in Preterm Babies: The Initial Brazilian Experience.. Arq Bras Cardiol 119(3):460-467 PMID: 36074378
- 4. Hung YC et al.. 2018. Molecular Mechanisms for Regulating Postnatal Ductus Arteriosus Closure.. Int J Mol Sci 19(7) PMID: 29941785
- 5. Sallmon H et al.. 2023. Platelets and ductus arteriosus closure in neonates.. Semin Perinatol 47(2):151719 PMID: 36925318
- 6. Tynan M. 1993. The ductus arteriosus and its closure.. N Engl J Med 329(21):1570-2 PMID: 8413481
- 7. Van Overmeire B et al.. 2005. The pharmacologic closure of the patent ductus arteriosus.. Semin Fetal Neonatal Med 10(2):177-84 PMID: 15701582
- 8. Lembo C et al.. 2024. Renal function after ductus arteriosus transcatheter closure with or without angiography in very preterm infants.. Acta Paediatr 113(5):955-961 PMID: 38180109
